Wedbush began coverage on shares of Zenas Biopharma (NASDAQ:ZBIO – Free Report) in a research report released on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $35.00 price target on the stock.
Separately, Guggenheim reiterated a “buy” rating and set a $45.00 target price on shares of Zenas Biopharma in a research note on Wednesday, March 12th.
Read Our Latest Stock Report on Zenas Biopharma
Zenas Biopharma Price Performance
About Zenas Biopharma
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Featured Articles
- Five stocks we like better than Zenas Biopharma
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Zenas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
